Loading...
Docoh

Selecta Biosciences (SELB)

Selecta Biosciences Inc. is leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With a proven ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well as restore the body's natural self-tolerance in autoimmune diseases. The company's first program aimed at addressing immunogenicity to AAV gene therapies is expected to enter clinical trials in early 2021 in partnership with AskBio for the treatment of methylmalonic acidemia (MMA), a rare metabolic disorder. A wholly-owned program focused on addressing IgA nephropathy driven by ImmTOR and a therapeutic enzyme is also in development among additional product candidates. Selecta recently licensed its Phase 3 clinical product candidate, SEL-212, in chronic refractory gout to Sobi.

SELB stock data

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

8 Aug 22
28 Sep 22
31 Dec 22
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 139.44M 139.44M 139.44M 139.44M 139.44M 139.44M
Cash burn (monthly) (no burn) (no burn) (no burn) (no burn) 4.09M 5.53M
Cash used (since last report) n/a n/a n/a n/a 12.08M 16.33M
Cash remaining n/a n/a n/a n/a 127.35M 123.11M
Runway (months of cash) n/a n/a n/a n/a 31.1 22.3

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
2 Sep 22 Carsten Brunn Common Stock Sell Dispose S No No 1.8478 4,768 8.81K 540,559
1 Sep 22 Carsten Brunn Common Stock Option exercise Acquire M No No 0 10,937 0 545,327
1 Sep 22 Carsten Brunn RSU Common Stock Option exercise Dispose M No No 0 10,937 0 10,938
13 Jun 22 Cox Carrie Smith Common Stock Buy Acquire P No No 1.1523 130,000 149.8K 212,881
1 Jun 22 Carsten Brunn Common Stock Option exercise Acquire M No No 0 10,938 0 534,390
1 Jun 22 Carsten Brunn RSU Common Stock Option exercise Dispose M No No 0 10,938 0 21,875
9 May 22 Barabe Timothy C Common Stock Buy Acquire P No No 0.7744 50,000 38.72K 250,013
11 Apr 22 Timothy A Springer Common Stock Buy Acquire P Yes No 0 6,681,600 0 29,868,490
11 Apr 22 Timothy A Springer Warrant Common Stock Grant Acquire A Yes No 1.55 5,011,200 7.77M 5,011,200
57.7% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 94 102 -7.8%
Opened positions 20 12 +66.7%
Closed positions 28 17 +64.7%
Increased positions 25 27 -7.4%
Reduced positions 34 41 -17.1%
13F shares Current Prev Q Change
Total value 242.97M 158.11M +53.7%
Total shares 88.19M 85.13M +3.6%
Total puts 60.7K 25.1K +141.8%
Total calls 82.7K 42.9K +92.8%
Total put/call ratio 0.7 0.6 +25.4%
Largest owners Shares Value Change
Timothy A Springer 25.16M $80M 0.0%
Mangrove Partners 7.26M $9.51M NEW
Vanguard 5.53M $7.25M -2.8%
Artal 4.88M $6.4M +22.1%
Endurant Capital Management 4.61M $6.04M +33.6%
NanoDimension 4M $5.24M +9.7%
EcoR1 Capital 3.5M $4.59M NEW
Mangrove Partners Master Fund 3.33M $10.1M 0.0%
Boxer Capital 3.28M $4.3M 0.0%
BLK Blackrock 2.37M $3.11M -64.9%
Largest transactions Shares Bought/sold Change
Mangrove Partners 7.26M +7.26M NEW
BLK Blackrock 2.37M -4.39M -64.9%
EcoR1 Capital 3.5M +3.5M NEW
Nuveen Asset Management 0 -2.07M EXIT
STT State Street 385.8K -1.41M -78.5%
Endurant Capital Management 4.61M +1.16M +33.6%
K2 Principal Fund 1.01M +1.01M NEW
Two Sigma Investments 127.92K -1M -88.7%
Acadian Asset Management 1.09M +906.41K +498.3%
Renaissance Technologies 588.38K -902.02K -60.5%

Financial report summary

?
Risks
  • Our business and operations, including our development programs, could be materially disrupted in the event of system failures, security breaches, violations of data protection laws or data loss or damage by us or third parties on which we rely, including our CROs or other contractors or consultants.
Management Discussion
  • Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
  • We are a clinical-stage biopharmaceutical company. Our ImmTOR® platform encapsulates rapamycin, also known as sirolimus, an FDA approved immunomodulator, in biodegradable nanoparticles ImmTOR is designed to induce antigen-specific immune tolerance.
  • We continually seek to enhance ImmTOR. In recent preclinical studies we have conducted, we have observed that ImmTOR may have synergistic activity with interleukin-2, or IL-2, molecules that have been engineered to be selective for regulatory T cells, or Tregs. Treg-selective IL-2 mutant molecules, or IL-2 muteins, have been shown to transiently expand all pre-existing Tregs in preclinical studies conducted by others. We have observed in preclinical studies that the combination of ImmTOR, a Treg-selective IL-2 mutein and an antigen elicited an approximately three-fold increase in antigen-specific Tregs beyond ImmTOR alone with evidence of enhanced durability of immune tolerance and the potential for ImmTOR dose sparing. This combination of ImmTOR with a Treg selective IL-2 molecule represents an evolution of the ImmTOR platform, which we call ImmTOR-IL™. We believe this combination has the potential to be a best-in-class therapy in diseases where expansion of total Tregs may prove beneficial.

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: acquisition, assertion, Certificate, Charter, confidential, confidentiality, conform, constantly, cyber, damage, deliberate, detecting, difficulty, disclaim, effort, electrical, frequency, hearing, inappropriate, midpoint, misappropriation, persistent, personally, pose, privacy, ransomware, reclassified, remediate, reproduce, reputation, reputational, Secretary, separate, Similarly, sophistication, stored, telecommunication, terrorism, unauthorized, vulnerability, vulnerable, war, world
Removed: decreased, immaterial

Patents

Utility
Methods and compositions related to combined treatment with antiinflammatories and synthetic nanocarriers comprising an immunosuppressant
30 Aug 22
Provided herein are methods and compositions, such as kits, related to compositions comprising synthetic nanocarriers comprising an immunosuppressant and compositions comprising an uricase and a composition comprising an anti-inflammatory therapeutic.
Utility
Methods and Compositions for Reducing Immune Responses Against Immunoglobulin Proteases
5 May 22
Disclosed are methods and related compositions for administering an immunoglobulin (Ig) protease in combination with synthetic nanocarriers comprising immunosuppressants.
Utility
Methods of Administering Immunosuppressants Having a Specified Pharmacodynamic Effective Life and Therapeutic Macromolecules for the Induction of Immune Tolerance
10 Mar 22
This invention relates to methods that provide immunosuppressants and therapeutic macromolecules that are administered within a pharmacodynamically effective window of the immunosuppressants to induce immune tolerance to the therapeutic macromolecules.
Utility
Methods for providing polymeric synthetic nanocarriers for generating antigen-specific tolerance immune responses
1 Feb 22
Disclosed are synthetic nanocarrier compositions that provide controlled release of immunosuppressants as well as related methods.
Utility
Methods and Compositions Related to Synthetic Nanocarriers
7 Oct 21
This invention relates to synthetic nanocarriers, and related compositions and methods, including wherein the synthetic nanocarrier compositions can be lyophilized, are in a lyophilized form, or a reconstituted composition thereof.